CHOLANGIOCARCINOMA MARKET ANALYSIS

Market News

Global Cholangiocarcinoma Market- Key Developments

• On April 05, 2023, Verismo Therapeutics, a clinical-stage CAR T company and pioneer of the novel KIR-CAR platform technology, announced that it had received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SynKIR-110, an investigational new drug administered intravenously for the treatment of mesothelin-expressing mesothelioma, cholangiocarcinoma, and ovarian cancer.
• In October 2022, Taiho Pharmaceutical Co., Ltd., a subsidiary of Otsuka Holdings Co., Ltd., announced that its U.S. subsidiary, Taiho Oncology, Inc. (“Taiho Oncology”) had received U.S. Food and Drug Administration (FDA) approval for Futibatinib for the treatment of advanced or metastatic intrahepatic cholangiocarcinoma (iCCA).
• In September 2022, AstraZeneca, a global pharmaceutical company, announced that Imfinzi (durvalumab), a human monoclonal antibody that binds to the PD-L1 protein, had been approved in the U.S. by the FDA for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin).
• In September 2022, Specialised Therapeutics, a pharmaceutical company, announced that its PEMAZYRE (pemigatinib), a fibroblast growth factor receptor (FGFR) inhibitor, had been provisionally approved by the Therapeutic Goods Administration (TGA) for the treatment of advanced or metastatic cholangiocarcinoma.
• In April 2021, PlantPraxis Biotecnologia, a biopharmaceutical company that focuses on the rapid development and production of specialty antibody and protein drugs, and Bio-Manguinhos, a pharmaceutical company, announced a collaborative research and development agreement to develop a biosimilar, named pembrolizumab for the Brazil market. Pembrolizumab is widely used in immunotherapy to treat a variety of cancers including melanoma, cholangiocarcinoma, lung cancer, head and neck cancer, and stomach cancer.
• In February 2021, Dr Reddy's Laboratories, a pharmaceutical company, launched the cancer treatment drug capecitabine tablets in the U.S. market. The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the U.S. FDA. Dr. Reddy's Capecitabine Tablets, USP are available in dosages of 150 mg and 500 mg in bottle counts of 60 and 120, respectively.